Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
17043 | 557 | 43.3 | 82% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
1002 | 9892 | PHOSPHOLIPASE D//DIACYLGLYCEROL KINASE//PROTEIN KINASE C |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | BRYOSTATIN 1 | Author keyword | 77 | 65% | 13% | 73 |
2 | BRYOSTATIN | Author keyword | 55 | 61% | 10% | 58 |
3 | BRYOSTATINS | Author keyword | 27 | 78% | 3% | 18 |
4 | APLYSIATOXIN | Author keyword | 9 | 55% | 2% | 11 |
5 | MARINE BRYOZOAN | Author keyword | 6 | 58% | 1% | 7 |
6 | BUGULA NERITINA | Author keyword | 4 | 28% | 2% | 13 |
7 | BRYOSTATIN 11 | Author keyword | 3 | 100% | 1% | 3 |
8 | AURISTATIN PE | Author keyword | 3 | 50% | 1% | 4 |
9 | BRYOSTATIN 5 | Author keyword | 2 | 67% | 0% | 2 |
10 | PKC ACTIVATORS | Author keyword | 2 | 67% | 0% | 2 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | BRYOSTATIN 1 | 77 | 65% | 13% | 73 | Search BRYOSTATIN+1 | Search BRYOSTATIN+1 |
2 | BRYOSTATIN | 55 | 61% | 10% | 58 | Search BRYOSTATIN | Search BRYOSTATIN |
3 | BRYOSTATINS | 27 | 78% | 3% | 18 | Search BRYOSTATINS | Search BRYOSTATINS |
4 | APLYSIATOXIN | 9 | 55% | 2% | 11 | Search APLYSIATOXIN | Search APLYSIATOXIN |
5 | MARINE BRYOZOAN | 6 | 58% | 1% | 7 | Search MARINE+BRYOZOAN | Search MARINE+BRYOZOAN |
6 | BUGULA NERITINA | 4 | 28% | 2% | 13 | Search BUGULA+NERITINA | Search BUGULA+NERITINA |
7 | BRYOSTATIN 11 | 3 | 100% | 1% | 3 | Search BRYOSTATIN+11 | Search BRYOSTATIN+11 |
8 | AURISTATIN PE | 3 | 50% | 1% | 4 | Search AURISTATIN+PE | Search AURISTATIN+PE |
9 | BRYOSTATIN 5 | 2 | 67% | 0% | 2 | Search BRYOSTATIN+5 | Search BRYOSTATIN+5 |
10 | PKC ACTIVATORS | 2 | 67% | 0% | 2 | Search PKC+ACTIVATORS | Search PKC+ACTIVATORS |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | PYRAN ANNULATION | 53 | 95% | 3% | 18 |
2 | ACTIVATOR BRYOSTATIN 1 | 29 | 88% | 3% | 14 |
3 | POTENT ANTINEOPLASTIC AGENTS | 26 | 100% | 2% | 11 |
4 | C 17 C 27 FRAGMENT | 23 | 100% | 2% | 10 |
5 | AGENT BRYOSTATIN 1 | 20 | 100% | 2% | 9 |
6 | INTRAVENOUS BRYOSTATIN 1 | 18 | 89% | 1% | 8 |
7 | CLONOGENIC RESPONSE | 17 | 100% | 1% | 8 |
8 | BRYOSTATIN 1 | 16 | 30% | 8% | 45 |
9 | C1 C9 SEGMENT | 14 | 100% | 1% | 7 |
10 | BUGULA NERITINA | 12 | 36% | 5% | 27 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
The Chemistry and Biology of the Bryostatins: Potential PKC Inhibitors in Clinical Development | 2012 | 17 | 102 | 74% |
Bryostatin-1: A novel PKC inhibitor in clinical development | 2003 | 81 | 107 | 72% |
New Approaches to the Total Synthesis of the Bryostatin Antitumor Macrolides | 2010 | 50 | 160 | 63% |
Total synthesis of bryostatin 2 | 1999 | 193 | 101 | 51% |
Chemistry and clinical biology of the bryostatins | 2000 | 127 | 82 | 67% |
Function-oriented synthesis, step economy, and drug design | 2008 | 388 | 56 | 27% |
The chemistry and biology of the bryostatin antitumour macrolides | 2002 | 127 | 145 | 47% |
The clinical development of the bryostatins | 2002 | 62 | 67 | 78% |
Function through Synthesis-Informed Design | 2015 | 2 | 38 | 32% |
Marine natural products: Bryostatins in preclinical and clinical studies | 2014 | 5 | 29 | 72% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | INTERNAL MEDKARMANOS CANC | 2 | 50% | 0.5% | 3 |
2 | HEMATOL ONCOLKARMANOS CANC | 1 | 30% | 0.5% | 3 |
3 | EXPTL CHEMOTHER Y | 1 | 50% | 0.2% | 1 |
4 | HAEMATOL BR238 | 1 | 50% | 0.2% | 1 |
5 | MASS SPE OMETER IL | 1 | 50% | 0.2% | 1 |
6 | NAT RADIAT PONSE MECHANISMS GRP | 1 | 50% | 0.2% | 1 |
7 | GASTROINTESTINAL ONCOL NEW DRUG DEV | 0 | 33% | 0.2% | 1 |
8 | MASS SPEC | 0 | 33% | 0.2% | 1 |
9 | MED HEM ONC | 0 | 33% | 0.2% | 1 |
10 | PHASE 2 NETWORK | 0 | 33% | 0.2% | 1 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000203650 | ENZASTAURIN//C1 DOMAIN//INDOLACTAM |
2 | 0.0000165001 | DOLASTATIN 10//DIDEMNIN B//TZT 1027 |
3 | 0.0000114083 | UCN 01//7 HYDROXYSTAUROSPORINE//7 HYDROXYSTAUROSPORINE UCN 01 |
4 | 0.0000103224 | PROTEIN KINASE C ISOFORMS//PROTEIN KINASE C ISOZYMES//PROTEIN KINASE C SUBSPECIES |
5 | 0.0000101758 | PRINS CYCLIZATION//CENTROLOBINE//PRINS CYCLISATION |
6 | 0.0000084644 | AS101//SAFDIE AIDS IMMUNOL//CAIR |
7 | 0.0000079697 | DCP LA//ALPHA 7 ACH RECEPTOR//ALPHA 7 ACETYLCHOLINE RECEPTOR |
8 | 0.0000069281 | PAEDERUS//PEDERIN//PAEDERUS DERMATITIS |
9 | 0.0000066326 | REDUCTION DIASTEREOSELECTIVE//ALDOL PRODUCTS//HYDROXY AMIDES |
10 | 0.0000050169 | PERIPHERAL CELLS//GERIATR MEDKFC//NORMAL HUMAN SKIN FIBROBLASTS |